Latest Treatment of Chronic ITP
For adults with chronic ITP who are corticosteroid-dependent or unresponsive to corticosteroids, thrombopoietin receptor agonists (TPO-RAs) are the preferred second-line therapy, with either eltrombopag (oral daily) or romiplostim (weekly subcutaneous injection) as first choices. 1
Initial Corticosteroid Therapy
- Limit corticosteroid duration to ≤6 weeks (including taper) to minimize toxicity 1
- Corticosteroids achieve complete response in approximately 74% of patients, but only 50% maintain remission after discontinuation 2
- Steroid-related complications (hypertension, diabetes) occur in >10% of patients and remain a significant concern 3
Second-Line Treatment Algorithm for Chronic ITP (≥3 months)
The 2019 ASH guidelines establish a clear hierarchy for corticosteroid-refractory patients:
First Choice: TPO-RAs over Rituximab 1
TPO-RA Options:
- Eltrombopag: Oral daily dosing (preferred if patient values convenience of oral medication)
- Romiplostim: Weekly subcutaneous injection (preferred if patient wants to avoid daily medication and dietary restrictions)
- Avatrombopag: Newer FDA-approved oral agent 1, 4
Rationale for TPO-RA preference:
- More predictable response rates
- Avoids permanent immunosuppression
- Reversible upon discontinuation
- Cost-effective (eltrombopag ~$66,560 vs romiplostim ~$91,039 over 26 weeks) 1
Second Choice: Rituximab over Splenectomy 1
- Rituximab preferred when patient wishes to avoid surgery
- Avoids permanent anatomical change and infection risk
- Can be repeated if needed
Third Choice: Splenectomy 1
Delay splenectomy ≥1 year from diagnosis due to potential for spontaneous remission 1
Splenectomy considerations:
- Preferred for patients who value avoidance of long-term medication
- Preferred for those seeking durable response without ongoing therapy
- Mandatory pre-splenectomy requirements:
- Complete immunizations (pneumococcal, meningococcal, Haemophilus influenzae type B)
- Counseling on lifelong antibiotic prophylaxis
- Education on overwhelming post-splenectomy infection risk 1
Emerging Therapies (2024-2026 Updates)
Novel First-Line Combination Therapy 5
The 2026 ASH guidelines now conditionally recommend:
- Rituximab + corticosteroids OR TPO-RA + corticosteroids as initial therapy (rather than corticosteroids alone)
- This represents a paradigm shift toward upfront combination therapy for newly diagnosed ITP
Additional Second-Line Options 4, 6, 7
- Fostamatinib (spleen tyrosine kinase inhibitor): FDA-approved for refractory ITP 8, 9
- Hetrombopag: Additional TPO-RA option 4
- Investigational agents:
Treatment Selection Framework
Choose TPO-RA when:
- Patient requires reversible, non-immunosuppressive therapy
- Avoiding surgery is priority
- Predictable response needed
Choose Rituximab when:
- Patient wants to avoid daily/weekly medication
- Seeking potential cure without surgery
- TPO-RAs contraindicated or failed
Choose Splenectomy when:
- Patient values medication-free remission
- Failed or intolerant to TPO-RAs and rituximab
- Seeking most durable response
- ≥1 year has passed since diagnosis
Critical Management Points
- Ensure hematology follow-up within 24-72 hours of diagnosis or relapse 1
- Individualize based on:
- Bleeding frequency requiring hospitalization
- Comorbidities and bleeding risk
- Patient adherence capability
- Cost and availability
- Patient values regarding surgery vs. chronic medication 1
Common Pitfalls to Avoid
- Prolonged corticosteroid courses (>6 weeks) - increases toxicity without improving outcomes 1
- Rushing to splenectomy - delay ≥1 year for spontaneous remission potential 1
- Inadequate pre-splenectomy vaccination - must complete before surgery 1
- Ignoring quality of life outcomes - treatment decisions should incorporate patient-reported outcomes, not just platelet counts 1, 6